Reaction
Neovascularisation reporting signals
As of the last recalculation, Neovascularisation appears in 253 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is RIZATRIPTAN BENZOATE (PRR 649.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Rizatriptan Benzoate | 61 | 649.8 | 653.7 |
| Dimenhydrinate | 62 | 633.7 | 637.4 |
| Botulinum Toxin Type A | 59 | 509.6 | 512.0 |
| Valproate Sodium | 55 | 279.5 | 280.2 |
| Trazodone Hydrochloride | 37 | 227.8 | 228.3 |
| Prochlorperazine | 55 | 208.3 | 208.7 |
| Candesartan | 59 | 177.1 | 177.4 |
| Nifedipine | 64 | 149.0 | 149.2 |
| Clonidine | 59 | 123.3 | 123.4 |
| Divalproex Sodium | 50 | 109.9 | 110.0 |
| Propranolol Hydrochloride | 64 | 97.4 | 97.5 |
| Erenumab-Aooe | 50 | 92.8 | 92.9 |
| Venlafaxine | 59 | 88.1 | 88.2 |
| Ranibizumab | 25 | 85.9 | 85.9 |
| Metoclopramide Hydrochloride | 58 | 79.9 | 80.0 |
| Topiramate | 63 | 73.7 | 73.8 |
| Valproic Acid | 24 | 69.1 | 69.2 |
| Aflibercept | 7 | 19.0 | 19.0 |